Carlos Velasquez

Dr. Carlos Velasquez

Hospital Universitario Marqués de Valdecilla - Instituto de Investigación Valdecilla, Santander
+1
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in British Journal of Radiology
Verified
Journal Article
Open access
DMDavid Molina
David Molina
JPJulián Pérez-Beteta
Julián Pérez-Beteta
BLBelén Luque
Belén Luque
EAElena Arregui
Elena Arregui
MCManuel Calvo
Manuel Calvo
Víctor M. Pérez-GarcíaVíctor M. Pérez-García
Víctor M. Pérez-García
Objective:The main objective of this retrospective work was the study of three-dimensional (3D) heterogeneity measures of post-contrast pre-operative MR images acquired with T1 weighted sequences of patients with glioblastoma (GBM) as predictors of clinical outcome.Methods:79 patients from 3 hospitals were included in the study. 16 3D textural heterogeneity measures were computed including run-length matrix (RLM) features (regional heterogeneity) and co-occurrence matrix (CM) features (local heterogeneity). The significance of the results was studied using Kaplan–Meier curves and Cox proportional hazards analysis. Correlation between the variables of the study was assessed using the Spearman's correlation coefficient.Results:Kaplan–Meyer survival analysis showed that 4 of the 11 RLM features and 4 of the 5 CM features considered were robust predictors of survival. The median survival differences in the most significant cases were of over 6 months.Conclusion:Heterogeneity measures computed on the post-cont...

29 July 2019 in Journal of Oncology
Verified
Journal Article
Open access
Carlos VelasquezCarlos Velasquez
Carlos Velasquez
SMSheila Mansouri
Sheila Mansouri
CMCarla Mora
Carla Mora
FNFarshad Nassiri
Farshad Nassiri
SSSuganth Suppiah
Suganth Suppiah
JFJose L Fernandez-Luna
Jose L Fernandez-Luna
The invasive capacity of GBM is one of the key tumoral features associated with treatment resistance, recurrence, and poor overall survival. The molecular machinery underlying GBM invasiveness comprises an intricate network of signaling pathways and interactions with the extracellular matrix and host cells. Among them, PI3k/Akt, Wnt, Hedgehog, and NFkB play a crucial role in the cellular processes related to invasion. A better understanding of these pathways could potentially help in developing new therapeutic approaches with better outcomes. Nevertheless, despite significant advances made over the last decade on these molecular and cellular mechanisms, they have not been translated into the clinical practice. Moreover, targeting the infiltrative tumor and its significance regarding outcome is still a major clinical challenge. For instance, the pre- and intraoperative methods used to identify the infiltrative tumor are limited when trying to accurately define the tumor boundaries and the burden of tumor cells in the infiltrated parenchyma. Besides, the impact of treating the infiltrative tumor remains unclear. Here we aim to highlight the molecular and clinical hallmarks of invasion in GBM.

6 June 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DMDavid Molina
David Molina
JPJulián Pérez-Beteta
Julián Pérez-Beteta
AMAlicia Martínez-González
Alicia Martínez-González
JMJuan Martino
Juan Martino
Carlos VelasquezCarlos Velasquez
Carlos Velasquez
Víctor M. Pérez-GarcíaVíctor M. Pérez-García
Víctor M. Pérez-García
Textural measures have been widely explored as imaging biomarkers in cancer. However, their robustness under dynamic range and spatial resolution changes in brain 3D magnetic resonance images (MRI) has not been assessed. The aim of this work was to study potential variations of textural measures due to changes in MRI protocols. Twenty patients harboring glioblastoma with pretreatment 3D T1-weighted MRIs were included in the study. Four different spatial resolution combinations and three dynamic ranges were studied for each patient. Sixteen three-dimensional textural heterogeneity measures were computed for each patient and configuration including co-occurrence matrices (CM) features and run-length matrices (RLM) features. The coefficient of variation was used to assess the robustness of the measures in two series of experiments corresponding to (i) changing the dynamic range and (ii) changing the matrix size. No textural measures were robust under dynamic range changes. Entropy was the only textural feature robust under spatial resolution changes (coefficient of variation under 10% in all cases). Textural measures of three-dimensional brain tumor images are not robust neither under dynamic range nor under matrix size changes. Standards should be harmonized to use textural features as imaging biomarkers in radiomic-based studies. The implications of this work go beyond the specific tumor type studied here and pose the need for standardization in textural feature calculation of oncological images.

1 November 2016 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
DMDavid Molina
David Molina
JPJulián Pérez-Beteta
Julián Pérez-Beteta
AMAlicia Martínez-González
Alicia Martínez-González
JMJuan Martino
Juan Martino
Carlos VelasquezCarlos Velasquez
Carlos Velasquez
Víctor M. Pérez-GarcíaVíctor M. Pérez-García
Víctor M. Pérez-García

21 June 2016 in European Radiology
Verified
Journal Article
Closed access
PDF file
JPJulián Pérez-Beteta
Julián Pérez-Beteta
AMAlicia Martínez-González
Alicia Martínez-González
DMDavid Molina
David Molina
Mariano Amo-SalasMariano Amo-Salas
Mariano Amo-Salas
BLBelén Luque
Belén Luque
Víctor M. Pérez-GarcíaVíctor M. Pérez-García
Víctor M. Pérez-García

19 September 2016 in Oncogene
Verified
Journal Article
Open access
ATA Talamillo
A Talamillo
LGL Grande
L Grande
PRP Ruiz-Ontañon
P Ruiz-Ontañon
Carlos VelasquezCarlos Velasquez
Carlos Velasquez
PMP Mollinedo
P Mollinedo
JFJ L Fernandez-Luna
J L Fernandez-Luna
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes.